nodes	percent_of_prediction	percent_of_DWPC	metapath
Bevantolol—Verapamil—CACNB2—attention deficit hyperactivity disorder	0.00932	0.171	CrCbGaD
Bevantolol—ADRB1—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.00851	0.00901	CbGpPWpGaD
Bevantolol—ADRB2—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.00843	0.00892	CbGpPWpGaD
Bevantolol—Carvedilol—ADRA2C—attention deficit hyperactivity disorder	0.00837	0.154	CrCbGaD
Bevantolol—ADRB2—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.00833	0.00881	CbGpPWpGaD
Bevantolol—ADRB1—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.00819	0.00866	CbGpPWpGaD
Bevantolol—ADRB2—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.00801	0.00847	CbGpPWpGaD
Bevantolol—ADRB1—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.00793	0.00839	CbGpPWpGaD
Bevantolol—ADRA1A—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.00788	0.00834	CbGpPWpGaD
Bevantolol—ADRB2—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.00776	0.00821	CbGpPWpGaD
Bevantolol—Tamsulosin—DRD3—attention deficit hyperactivity disorder	0.00764	0.14	CrCbGaD
Bevantolol—ADRB1—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.00761	0.00805	CbGpPWpGaD
Bevantolol—ADRA1A—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.00758	0.00802	CbGpPWpGaD
Bevantolol—ADRB1—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00756	0.00799	CbGpPWpGaD
Bevantolol—ADRB2—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.00745	0.00788	CbGpPWpGaD
Bevantolol—ADRB1—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.00737	0.0078	CbGpPWpGaD
Bevantolol—ADRA1A—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.00733	0.00775	CbGpPWpGaD
Bevantolol—ADRB1—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00725	0.00766	CbGpPWpGaD
Bevantolol—ADRB2—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.00721	0.00763	CbGpPWpGaD
Bevantolol—ADRB1—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00716	0.00757	CbGpPWpGaD
Bevantolol—ADRA1A—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0071	0.00751	CbGpPWpGaD
Bevantolol—Verapamil—CACNA1C—attention deficit hyperactivity disorder	0.00709	0.13	CrCbGaD
Bevantolol—ADRB2—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00709	0.0075	CbGpPWpGaD
Bevantolol—ADRB2—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.007	0.0074	CbGpPWpGaD
Bevantolol—ADRA1A—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.00698	0.00738	CbGpPWpGaD
Bevantolol—Tamsulosin—ADRA2A—attention deficit hyperactivity disorder	0.00697	0.128	CrCbGaD
Bevantolol—ADRA1A—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.00689	0.00729	CbGpPWpGaD
Bevantolol—ADRB1—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00667	0.00705	CbGpPWpGaD
Bevantolol—ADRA1A—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.00663	0.00701	CbGpPWpGaD
Bevantolol—ADRB2—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00652	0.0069	CbGpPWpGaD
Bevantolol—ADRA1A—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.00642	0.00679	CbGpPWpGaD
Bevantolol—ADRA1A—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.00616	0.00651	CbGpPWpGaD
Bevantolol—ADRA1A—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.00597	0.00631	CbGpPWpGaD
Bevantolol—ADRA1A—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00586	0.0062	CbGpPWpGaD
Bevantolol—ADRA1A—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00579	0.00612	CbGpPWpGaD
Bevantolol—ADRB1—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.00558	0.0059	CbGpPWpGaD
Bevantolol—ADRB1—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00556	0.00588	CbGpPWpGaD
Bevantolol—ADRB2—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.00545	0.00577	CbGpPWpGaD
Bevantolol—ADRB2—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00543	0.00575	CbGpPWpGaD
Bevantolol—ADRA1A—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.0054	0.00571	CbGpPWpGaD
Bevantolol—Tamsulosin—DRD2—attention deficit hyperactivity disorder	0.00529	0.0971	CrCbGaD
Bevantolol—ADRB1—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00467	0.00494	CbGpPWpGaD
Bevantolol—ADRB2—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00457	0.00483	CbGpPWpGaD
Bevantolol—ADRA1A—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.0045	0.00475	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00381	0.00403	CbGpPWpGaD
Bevantolol—ADRA1A—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00378	0.004	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.0037	0.00391	CbGpPWpGaD
Bevantolol—Carvedilol—ADRA2A—attention deficit hyperactivity disorder	0.00357	0.0656	CrCbGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00317	0.00335	CbGpPWpGaD
Bevantolol—Verapamil—SLC6A4—attention deficit hyperactivity disorder	0.00314	0.0577	CrCbGaD
Bevantolol—ADRB1—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00314	0.00332	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.0031	0.00328	CbGpPWpGaD
Bevantolol—ADRB1—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.0031	0.00328	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.0031	0.00328	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00308	0.00326	CbGpPWpGaD
Bevantolol—ADRB2—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00307	0.00325	CbGpPWpGaD
Bevantolol—Propranolol—HTR1B—attention deficit hyperactivity disorder	0.00307	0.0563	CrCbGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00304	0.00321	CbGpPWpGaD
Bevantolol—ADRB2—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00303	0.00321	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00301	0.00319	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00271	0.00287	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00266	0.00281	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00265	0.00281	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0026	0.00275	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00256	0.00271	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00251	0.00266	CbGpPWpGaD
Bevantolol—ADRA1A—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00251	0.00265	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00249	0.00264	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00241	0.00255	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.0022	0.00232	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00215	0.00227	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00215	0.00227	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.0021	0.00223	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00207	0.00219	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00202	0.00214	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00202	0.00214	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00198	0.00209	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00188	0.00199	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00184	0.00195	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00184	0.00194	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0018	0.00191	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00175	0.00185	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00174	0.00184	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00174	0.00184	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00171	0.00181	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.0017	0.0018	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00169	0.00179	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00167	0.00177	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00166	0.00176	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00166	0.00175	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00164	0.00174	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00164	0.00173	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00163	0.00172	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00161	0.0017	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00161	0.0017	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00158	0.00167	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00158	0.00167	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00155	0.00164	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00153	0.00162	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00152	0.00161	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.0015	0.00158	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.0015	0.00158	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00149	0.00158	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00146	0.00155	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00145	0.00153	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00143	0.00151	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00142	0.0015	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00141	0.0015	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00141	0.00149	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00141	0.00149	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.0014	0.00148	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00139	0.00147	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00138	0.00146	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00137	0.00145	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00137	0.00145	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00135	0.00142	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00133	0.00141	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00131	0.00139	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.0013	0.00138	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00128	0.00136	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00128	0.00135	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00124	0.00131	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00123	0.0013	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00121	0.00128	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.0012	0.00127	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00117	0.00124	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00117	0.00124	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00115	0.00122	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00114	0.00121	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00114	0.00121	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00114	0.00121	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00114	0.0012	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00114	0.0012	CbGpPWpGaD
Bevantolol—ADRA1A—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00112	0.00119	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00112	0.00118	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00112	0.00118	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.0011	0.00117	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00109	0.00115	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00108	0.00114	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00107	0.00113	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00107	0.00113	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00106	0.00112	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00106	0.00112	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00106	0.00112	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00105	0.00111	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00105	0.00111	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00104	0.0011	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00104	0.0011	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00102	0.00107	CbGpPWpGaD
Bevantolol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.001	0.00106	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000999	0.00106	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000992	0.00105	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000977	0.00103	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000945	0.000999	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000934	0.000988	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000926	0.000979	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000923	0.000976	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000919	0.000971	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000914	0.000966	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000899	0.00095	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000894	0.000945	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000878	0.000929	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000867	0.000917	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000867	0.000917	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000858	0.000907	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000841	0.000889	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000808	0.000855	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000793	0.000839	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000776	0.00082	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000756	0.000799	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000743	0.000786	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000729	0.000771	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00072	0.000762	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000713	0.000754	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000704	0.000745	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000699	0.00074	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000693	0.000733	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000684	0.000724	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000678	0.000717	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000644	0.000681	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000642	0.000679	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00063	0.000667	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000629	0.000666	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000626	0.000663	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000624	0.00066	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000616	0.000651	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000614	0.000649	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000613	0.000649	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000613	0.000648	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00061	0.000646	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000606	0.000641	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000602	0.000637	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.0006	0.000635	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.0006	0.000635	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000593	0.000627	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00059	0.000624	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000589	0.000623	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000585	0.000619	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000583	0.000616	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000572	0.000605	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000567	0.000599	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000566	0.000599	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000564	0.000597	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000561	0.000593	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000557	0.000589	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000554	0.000586	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000552	0.000584	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00055	0.000582	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000545	0.000576	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000538	0.000569	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000521	0.000551	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000513	0.000542	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000509	0.000539	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000507	0.000536	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000505	0.000534	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000501	0.00053	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000497	0.000525	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000496	0.000525	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00049	0.000518	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000487	0.000515	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000473	0.000501	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000459	0.000485	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000457	0.000483	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000451	0.000477	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000445	0.000471	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000425	0.00045	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000416	0.00044	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000415	0.000439	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000395	0.000418	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000387	0.000409	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000372	0.000393	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000364	0.000385	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000359	0.00038	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000351	0.000371	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000346	0.000366	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000344	0.000364	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000338	0.000358	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000335	0.000354	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000329	0.000348	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000327	0.000346	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000325	0.000344	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000322	0.00034	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00032	0.000338	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000318	0.000336	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000303	0.00032	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000301	0.000318	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000296	0.000313	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00029	0.000307	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00028	0.000296	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000271	0.000286	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000266	0.000282	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000263	0.000278	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000245	0.000259	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000212	0.000224	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000207	0.000219	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000172	0.000181	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000112	0.000119	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.00011	0.000116	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.09e-05	9.61e-05	CbGpPWpGaD
